Pharma News

Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

Surgical removal of the tonsils and adenoids in children with snoring and mild breathing problems during sleep appears to improve their sleep, quality of life, and blood pressure a year after surgery, a clinical trial supported by the National Institutes of Health has found. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, is believed to be the first large, randomized trial to address the effects of adenotonsillectomy on children with mild sleep-disordered breathing (SDB).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

To speed up their growth, leukemia cells typically activate the recycling of cellular structures – enabling them to dispose of defective components and better supply themselves with building materials. Researchers at Goethe University Frankfurt have now shown that leukemia cells with a very common mutation activate specific genes that are important for this recycling process. Their findings, published in the journal Cell Reports, open up new therapeutic options for the future.

Self-folding polymers containing gadolinium forming nanosized complexes could be the key to enhanced magnetic resonance imaging and next-generation drug delivery, as demonstrated by scientists at Tokyo Tech. Thanks to their small size, low toxicity, and good tumor accumulation and penetration, these complexes represent a leap forward in contrast agents for cancer diagnosis, as well as neutron capture radiotherapy.

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]).

Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening.

A new study from Mass Eye and Ear investigators shows that individuals who report tinnitus, which present as a ringing in the ears in more than one out of ten adults worldwide, are experiencing auditory nerve loss that is not picked up by conventional hearing tests.

A simple-to-apply, needle-free vaccine patch is being developed to protect people from the potentially deadly mosquito-borne Zika virus.

A prototype using The University of Queensland-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP) has delivered a University of Adelaide-developed vaccine and elicited an effective immune response to Zika virus in mice.